Novo Nordisk A/S

DB:NOVA Stock Report

Market Cap: €457.6b

Novo Nordisk Past Earnings Performance

Past criteria checks 4/6

Novo Nordisk has been growing earnings at an average annual rate of 19.7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 17.8% per year. Novo Nordisk's return on equity is 78.6%, and it has net margins of 35%.

Key information

19.7%

Earnings growth rate

21.1%

EPS growth rate

Pharmaceuticals Industry Growth7.3%
Revenue growth rate17.8%
Return on equity78.6%
Net Margin35.0%
Next Earnings Update05 Feb 2025

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Novo Nordisk makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

DB:NOVA Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24270,58394,72165,72237,606
30 Jun 24258,00389,89863,20536,246
31 Mar 24244,24389,27662,52832,907
31 Dec 23232,26183,68361,59831,029
30 Sep 23214,49075,31258,06329,308
30 Jun 23201,32567,23956,59726,813
31 Mar 23188,29061,12953,01424,809
31 Dec 22176,95455,52550,68423,287
30 Sep 22167,19552,82548,41521,021
30 Jun 22157,25150,53945,94919,640
31 Mar 22149,02749,34443,02318,461
31 Dec 21140,80047,75741,05817,199
30 Sep 21134,60546,18339,20016,273
30 Jun 21129,91044,36238,23715,932
31 Mar 21126,87542,86437,55715,279
31 Dec 20126,94642,13836,88615,462
30 Sep 20127,22541,53736,69314,913
30 Jun 20126,57541,43336,28314,603
31 Mar 20126,60540,40336,49014,869
31 Dec 19122,02138,95135,83014,220
30 Sep 19119,33638,73135,05614,352
30 Jun 19116,82137,57434,34614,395
31 Mar 19114,19238,32233,85514,134
31 Dec 18111,83138,62833,31314,805
30 Sep 18110,09138,38432,72914,244
30 Jun 18108,94339,11732,06213,928
31 Mar 18110,17438,72531,73914,046
31 Dec 17111,69638,13032,12414,014
30 Sep 17113,27638,57631,78614,501
30 Jun 17114,19938,60932,26814,631
31 Mar 17113,02038,62632,39014,548
31 Dec 16111,78037,92532,33914,563
30 Sep 16111,08437,48432,46713,884
30 Jun 16110,33936,06432,49513,715
31 Mar 16109,93934,43932,81713,419
31 Dec 15107,92734,86032,16913,608
30 Sep 15103,63633,13130,71213,616
30 Jun 1599,09331,24829,57813,381
31 Mar 1593,66329,89927,87013,421
31 Dec 1488,80626,48126,76013,762
30 Sep 1485,91926,00526,57112,863
30 Jun 1484,18125,92026,15312,604
31 Mar 1483,93225,66026,44812,244
31 Dec 1383,57225,18426,88811,733

Quality Earnings: NOVA has a high level of non-cash earnings.

Growing Profit Margin: NOVA's current net profit margins (35%) are lower than last year (35.1%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: NOVA's earnings have grown by 19.7% per year over the past 5 years.

Accelerating Growth: NOVA's earnings growth over the past year (25.8%) exceeds its 5-year average (19.7% per year).

Earnings vs Industry: NOVA earnings growth over the past year (25.8%) exceeded the Pharmaceuticals industry 25.4%.

Return on Equity

High ROE: NOVA's Return on Equity (78.6%) is considered outstanding.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 01:17
End of Day Share Price 2024/12/18 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Novo Nordisk A/S is covered by 71 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
null nullABG Sundal Collier
Kamla SinghAlphaValue
Gerhard SchwarzBaader Helvea Equity Research